Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,850,892
  • Shares Outstanding, K 71,949
  • Annual Sales, $ 47,070 K
  • Annual Income, $ -223,860 K
  • EBIT $ -332 M
  • EBITDA $ -339 M
  • 60-Month Beta 2.28
  • Price/Sales 127.06
  • Price/Cash Flow N/A
  • Price/Book 6.28

Options Overview Details

View History
  • Implied Volatility 52.43% (-0.86%)
  • Historical Volatility 108.19%
  • IV Percentile 3%
  • IV Rank 5.27%
  • IV High 153.30% on 12/05/25
  • IV Low 46.82% on 08/18/25
  • Expected Move (DTE 20) 8.22 (10.11%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 57
  • Volume Avg (30-Day) 443
  • Put/Call OI Ratio 1.64
  • Today's Open Interest 3,281
  • Open Int (30-Day) 8,465
  • Expected Range 73.10 to 89.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.78
  • Number of Estimates 12
  • High Estimate -0.41
  • Low Estimate -0.95
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +11.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.69 +27.68%
on 12/02/25
103.00 -21.05%
on 12/08/25
+13.46 (+19.83%)
since 11/26/25
3-Month
54.09 +50.34%
on 10/01/25
103.00 -21.05%
on 12/08/25
+25.07 (+44.57%)
since 09/26/25
52-Week
19.44 +318.31%
on 04/09/25
103.00 -21.05%
on 12/08/25
+39.30 (+93.53%)
since 12/26/24

Most Recent Stories

More News
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 81.32 (-2.18%)
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial  KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported...

KYMR : 81.32 (-2.18%)
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 81.32 (-2.18%)
Stocks Retreat as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.35%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.45%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.25%....

RRC : 35.32 (+0.20%)
AVGO : 352.13 (+0.55%)
RIVN : 20.90 (-1.09%)
$IUXX : 25,644.39 (-0.05%)
ASML : 1,072.75 (+0.68%)
ZNH26 : 112-185s (+0.06%)
CRWV : 76.42 (-3.11%)
TSLA : 475.19 (-2.10%)
ESH26 : 6,979.25s (-0.05%)
PSKY : 13.59 (-1.09%)
GFS : 35.81 (+0.17%)
LRCX : 178.07 (+0.42%)
Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 81.32 (-2.18%)
Stocks Pressured by Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.20%. December E-mini...

RRC : 35.32 (+0.20%)
AVGO : 352.13 (+0.55%)
RIVN : 20.90 (-1.09%)
$IUXX : 25,644.39 (-0.05%)
ASML : 1,072.75 (+0.68%)
ZNH26 : 112-185s (+0.06%)
COMP : 10.59 (-0.84%)
CRWV : 76.42 (-3.11%)
TSLA : 475.19 (-2.10%)
ESH26 : 6,979.25s (-0.05%)
LRCX : 178.07 (+0.42%)
AMD : 214.99 (-0.02%)
Stocks Mixed as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.33%. December E-mini S&P...

MSTR : 158.81 (+0.06%)
RRC : 35.32 (+0.20%)
AVGO : 352.13 (+0.55%)
GLXY : 23.40 (-4.22%)
RIVN : 20.90 (-1.09%)
$IUXX : 25,644.39 (-0.05%)
COIN : 236.90 (-1.18%)
ASML : 1,072.75 (+0.68%)
ZNH26 : 112-185s (+0.06%)
COMP : 10.59 (-0.84%)
CRWV : 76.42 (-3.11%)
TSLA : 475.19 (-2.10%)
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from...

KYMR : 81.32 (-2.18%)
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage...

KYMR : 81.32 (-2.18%)
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621...

KYMR : 81.32 (-2.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 84.25
2nd Resistance Point 83.55
1st Resistance Point 82.44
Last Price 81.32
1st Support Level 80.62
2nd Support Level 79.92
3rd Support Level 78.81

See More

52-Week High 103.00
Last Price 81.32
Fibonacci 61.8% 71.08
Fibonacci 50% 61.22
Fibonacci 38.2% 51.36
52-Week Low 19.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar